Proteomics for precision medicine: Next-generation testing to indicate future cardiovascular risk and improve outcomes
Proteomics for precision medicine: Next-generation testing to
indicate future cardiovascular risk and improve outcomes
Proteomic testing can reveal multiple answers to clinical questions that allow providers to better predict, monitor, and prevent the escalation of cardiovascular disease (CVD). This allows providers to move the needle away from the practice of late-stage treatment and toward treating at-risk patients sooner and before a major cardiovascular (CV) event.
Topics covered include:
- The capabilities of proteomics
- How comprehensive protein detection technology can accurately predict major cardiovascular events
- How proteomic testing can ultimately improve outcomes
Nelson Trujillo, MD
Cardiologist
Boulder Heart at Anderson Medical Center
Rosalyn Gill, PhD
Vice President, Medical Affairs
SomaLogic, Inc.
Todd Johnson
Executive Vice President, Diagnostics
Business Unit
SomaLogic, Inc.
Proteomics for precision medicine: Next-generation testing to indicate future cardiovascular risk and improve outcomes
A presentation by Nelson Trujillo, MD, Rosalyn Gill, PhD, and Todd Johnson
More webinars
WebinarEvaluation of precision and correlation for the latest proteomic platforms
The field of proteomics is rapidly advancing, enabling precise measurement of thousands of proteins, particularly those in higher abundance. This webcast will explore significant differences in precision within and across the latest large-scale proteomic platforms and their intercorrelations, based on blind duplicate split assays of the leading modified aptamer-based 11K and antibody proximity ligation-based 5K platforms. Each platform exhibits distinct strengths and limitations, requiring careful consideration prior to implementation in individual studies.
WebinarScaling Proteomics: Balancing Performance and Measuring Enough Proteins
As proteomics platforms have advanced, the number of proteins measured and sample throughput have dramatically increased. However, have sacrifices or trade-offs been necessary to make these gains? To find out, Stephen Williams will analyze how the performance of proteomics platforms has changed over time, comparing precision, sensitivity and specificity as throughput increases.
WebinarFrom discovery to clinical insights – the power of integrating proteomics and genomics data
The value of adding high-plex proteomics to existing genomics data and how proteogenomic approaches accelerate drug target discovery and repurposing. Watch this presentation given by Maik Pietzner, PhD, at ESHG 2024.